Zalicus is a biopharmaceutical company engaged in developing drug candidates with a focus on the treatment of pain. Co.'s primary product candidate is Z160, an oral N-type calcium channel blocker that Co. is seeking to develop for the treatment of chronic pain. Co.'s other product candidate is Z944, an oral T-type calcium channel blocker that Co. is seeking to develop for the treatment of pain indications. In addition, Co. is performing discovery research and preclinical development activities on its proprietary selective ion channel modulators targeting the Nav1.7 sodium channel as well as N-type and T-type calcium channels, as part of a research collaboration with Hydra Biosciences, Inc.